Sarcopenia, or a loss of muscle mass and strength, occurs in nearly one-quarter of systemic sclerosis (SSc) patients and is linked to a low body mass index (BMI) and high levels of C-reactive protein (CRP), according to a new study in Thailand. Patients with a low BMI —…
In patients with systemic sclerosis, low levels in the blood of two proteins, SIRT1 and SIRT3, are associated with poor lung function, widespread skin scarring, and inflammatory damage to the small blood vessels, a recent study shows. Results suggest that SIRT1 and SIRT3 may be useful biomarkers to predict…
Eight weeks of treatment with a small molecule called paquinimod significantly reduced the number of myofibroblasts — cells that drive scarring — in people with scleroderma, a small clinical trial reported. Findings also suggested that paquinimod may lessen type I interferon (IFN) activity, a relevant scleroderma biomarker, and appeared…
Get regular updates to your inbox.